Monaco

Monaco appears to have a small, tightly controlled medical and regulatory environment for psychedelics. Public sources show a restrictive narcotics framework, alongside a mental-health system with psychiatry, addiction-prevention and specialist care pathways; however, there is no public evidence of routine psychedelic treatment programmes in the Principality.

Ask Blossom about this country

Data updated July 15, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inMonaco.

1
The public legal signal is prohibition-first: Monaco has a formal controlled-substances framework rather than an open-access psychedelic model.
2
Official health-planning documents acknowledge innovative psychiatry, but they do not establish a routine psychedelic treatment programme.
3
The strongest documented clinical ecosystem signal is psychiatric and addiction care capacity under the Department of Health Affairs, not psychedelic-specific services.
4
Blossom's linked-trial picture is consistent with a very small research footprint: one linked trial, none active, and no visible event ecosystem.
5
Ketamine is the most plausible near-term medical comparator in Monaco, but available public sources do not support claiming a specific local psychedelic access pathway beyond general controlled-medicine practice.

Research and Access Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Monaco.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Ketamine(1)

Medical Access

Monaco maintains a restrictive controlled-substances regime: classic psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) are treated as illicit with no routine medical programs outside approved research. Esketamine (Spravato) is authorised at the European level and therefore may be prescribed/obtained within Monaco subject to national/ministerial marketing and reimbursement decisions; racemic ketamine is used off-label in psychiatric practice in Europe but access is typically private and not routinely reimbursed without...

View trials→View stakeholders→Open access guide→

Regulatory Status

Monaco maintains a restrictive controlled-substances regime. The 1970 stupéfiants law and the 2020 ministerial list of psychotropic substances indicate that classic psychedelics and related compounds are treated as controlled/illicit unless specifically authorised, while the government's mental-health materials mention S-ketamine only as part of service planning rather than as a general access pathway. Any medical use would therefore appear to depend on standard controlled-medicine rules, specialist prescribing and national authorisation decisions; exact patient access and reimbursement pathways are not clearly public and should be treated cautiously.